Safety, tolerability, and acceptability of Lactobacillus crispatus CTV-05 (LACTIN-V) in pregnant women at high-risk of preterm birth
In: Beneficial MicrobesMarch of Dimes European Prematurity Research Centre, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, UK, United Kingdom.
Search for other papers by E. Bayar in
Current site
Google Scholar
March of Dimes European Prematurity Research Centre, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, UK, United Kingdom.
Tommy’s National Centre for Miscarriage Research. Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, United Kingdom.
Search for other papers by D.A. MacIntyre in
Current site
Google Scholar
March of Dimes European Prematurity Research Centre, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, UK, United Kingdom.
The Parasol Foundation Centre for Women’s Health and Cancer Research, St Mary’s Hospital, Imperial College Healthcare NHS Trust, London, W2 1NY.
Search for other papers by L. Sykes in
Current site
Google Scholar
March of Dimes European Prematurity Research Centre, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, UK, United Kingdom.
Search for other papers by K. Mountain in
Current site
Google Scholar
Search for other papers by T.P. Parks in
Current site
Google Scholar
Search for other papers by P.P. Lee in
Current site
Google Scholar
March of Dimes European Prematurity Research Centre, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, UK, United Kingdom.
Tommy’s National Centre for Miscarriage Research. Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, United Kingdom.
Search for other papers by P.R. Bennett in
Current site
Google Scholar
The vaginal microbiota is a determinant for the risk of preterm birth (PTB). Dominance of the vaginal niche by Lactobacillus crispatus associates with term delivery. This is the first observational clinical study of live vaginal biotherapeutics (Lactobacillus crispatus CTV-05 (LACTIN-V)) in pregnant women at high-risk of PTB. The primary aim was to explore safety, tolerability and acceptability of LACTIN-V in pregnancy. Women were offered a course of LACTIN-V at 14 weeks gestation for five consecutive days followed by weekly administration for six weeks. Participants were followed up at 15, 18-, 20-, 28- and 36-weeks’ gestation and at delivery for assessment of adverse events, compliance and tolerability. Participants completed a questionnaire to gauge experience and acceptability. In total, 73 women were recruited, of whom eight withdrew, leaving a final cohort size of 61. Self-reported compliance to the course was high (56/60, 93%). Solicited adverse events were reported in 13 women (19%) including changes in vaginal discharge, odour, colour or consistency of urine, itching and vaginal bleeding. One unsolicited adverse event was reported as haematuria at 38 weeks gestation, but was judged to be unrelated to LACTIN-V. No serious adverse events occurred. One mild adverse event led to study withdrawal. Thirty-one women completed an experience and acceptability questionnaire. Women found LACTIN-V easy and comfortable to use and the majority (30/31, 97%) would use LACTIN-V in future pregnancies. Eight women (8/31, 26%) found the schedule of use difficult to remember. The rate of PTB <34 weeks in this cohort was 3.3% compared to 7% in a historical cohort of 2,190 women at similar background PTB risk. With satisfactory uptake and good compliance, we demonstrate that LACTIN-V is safe and accepted in pregnancy, with high tolerability. Further studies are needed to assess colonisation of Lactobacillus crispatus CTV-05 and clinical efficacy.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
-
Anahtar, M.N., Gootenberg, D.B., Mitchell, C.M. and Kwon, D.S., 2018. Cervicovaginal microbiota and reproductive health: the virtue of simplicity. Cell Host and Microbe 23: 159-168. https://doi.org/10.1016/j.chom.2018.01.013
-
Baldwin, E.A., Walther-Antonio, M., MacLean, A.M., Gohl, D.M., Beckman, K.B., Chen, J., White, B., Creedon, D.J. and Chia, N., 2015. Persistent microbial dysbiosis in preterm premature rupture of membranes from onset until delivery. PeerJ 3: e1398.https://doi.org/10.7717/peerj.1398
-
Bohbot, J., Daraï, E., Bretelle, F., Brami, G., Daniel, C. and Cardot, J., 2018. Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence. Journal of Gynecology, Obstetrics and Human Reproduction 47: 81-86. https://doi.org/10.1016/j.jogoh.2017.11.005
-
Brocklehurst, P., Gordon, A., Heatley, E. and Milan, S.J., 2013. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD000262.pub4
-
Brown, R.G., Al-Memar, M., Marchesi, J.R., Lee, Y.S., Smith, A., Chan, D., Lewis, H., Kindinger, L., Terzidou, V., Bourne, T., Bennett, P.R. and MacIntyre, D.A., 2019. Establishment of vaginal microbiota composition in early pregnancy and its association with subsequent preterm prelabor rupture of the fetal membranes. Translational Research 207: 30-43. https://doi.org/10.1016/j.trsl.2018.12.005
-
Brown, R.G., Marchesi, J.R., Lee, Y.S., Smith, A., Lehne, B., Kindinger, L.M., Terzidou, V., Holmes, E., Nicholson, J.K. and Bennett, P.R., 2018. Vaginal dysbiosis increases risk of preterm fetal membrane rupture, neonatal sepsis and is exacerbated by erythromycin. BMC Medicine 16: 1-15. https://doi.org/10.1186/s12916-017-0999-x
-
Butler, D.S., Silvestroni, A. and Stapleton, A.E., 2016. Cytoprotective effect of Lactobacillus crispatus CTV-05 against uropathogenic E. coli. Pathogens 5: 27. https://doi.org/10.3390/pathogens5010027
-
Chan, D., Bennett, P.R., Lee, Y.S., Kundu, S., Teoh, T., Adan, M., Ahmed, S., Brown, R.G., David, A.L. and Lewis, H.V., 2022. Microbial-driven preterm labour involves crosstalk between the innate and adaptive immune response. Nature Communications 13: 975. https://doi.org/10.1038/s41467-022-28620-1
-
Charbonneau, M.R., Isabella, V.M., Li, N. and Kurtz, C.B., 2020. Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nature Communications 11: 1738.https://doi.org/10.1038/s41467-020-15508-1
-
Ciandrini, E., Campana, R., Casettari, L., Perinelli, D.R., Fagioli, L., Manti, A., Palmieri, G.F., Papa, S. and Baffone, W., 2016. Characterization of biosurfactants produced by Lactobacillus spp. and their activity against oral streptococci biofilm. Applied Microbiology AND Biotechnology 100: 6767-6777. https://doi.org/10.1007/s00253-016-7531-7
-
Cohen, C.R., Wierzbicki, M.R., French, A.L., Morris, S., Newmann, S., Reno, H., Green, L., Miller, S., Powell, J., Parks, T. and Hemmerling, A., 2020. Randomized trial of LACTIN-V to prevent recurrence of bacterial vaginosis. New England Journal of Medicine 382: 1906-1915. https://doi.org/10.1056/NEJMoa1915254
-
Coman, M., Verdenelli, M., Cecchini, C., Silvi, S., Orpianesi, C., Caspani, M., Mondello, F. and Cresci, A., 2015. In vitro evaluation on HeLa cells of protective mechanisms of probiotic lactobacilli against Candida clinical isolates. Journal of Applied Microbiology 119: 1383-1390. https://doi.org/10.1111/jam.12947
-
Coomarasamy, A., Harb, H.M., Devall, A.J., Cheed, V., Roberts, T.E., Goranitis, I., Ogwulu, C.B., Williams, H.M., Gallos, I.D. and Eapen, A., 2020. Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. Health Technology Assessment 24 (33): 1-70. https://doi.org/10.3310/hta24330
-
Czaja, C.A., Stapleton, A.E., Yarova-Yarovaya, Y. and Stamm, W.E., 2007. Phase I trial of a Lactobacillus crispatus vaginal suppository for prevention of recurrent urinary tract infection in women. Infectious Diseases in Obstetrics and Gynecology 2007: 035387. https://doi.org/10.1155/2007/35387
-
DiGiulio, D.B., Callahan, B.J., McMurdie, P.J., Costello, E.K., Lyell, D.J., Robaczewska, A., Sun, C.L., Goltsman, D.S., Wong, R.J. and Shaw, G., 2015. Temporal and spatial variation of the human microbiota during pregnancy. Proceedings of the National Academy of Sciences of the USA 112: 11060-11065. https://doi.org/10.1073/pnas.1502875112
-
Elovitz, M.A., Gajer, P., Riis, V., Brown, A.G., Humphrys, M.S., Holm, J.B. and Ravel, J., 2019. Cervicovaginal microbiota and local immune response modulate the risk of spontaneous preterm delivery. Nature Communications 10: 1305. https://doi.org/10.1038/s41467-019-09285-9
-
Food and Drug Administration (FDA), 2016. Guidance for Industry. Early clinical trials with live biotherapeutic products: Chemistry, manufacturing, and control information. U.S. Department of Health and Human Services, FDA, Silver Spring, MD, USA. Available at: https://www.fda.gov/media/82945/download
-
Gajer, P., Brotman, R.M., Bai, G., Sakamoto, J., Schütte, U.M., Zhong, X., Koenig, S.S., Fu, L., Ma, Z.S. and Zhou, X., 2012. Temporal dynamics of the human vaginal microbiota. Science Translational Medicine 4: 132ra152. https://doi.org/10.1126/scitranslmed.3003605
-
Goldenberg, R.L., Culhane, J.F., Iams, J.D. and Romero, R., 2008. Epidemiology and causes of preterm birth. The Lancet 371: 75-84. https://doi.org/10.1016/S0140-6736(08)60074-4
-
Grev, J., Berg, M. and Soll, R., 2018. Maternal probiotic supplementation for prevention of morbidity and mortality in preterm infants. Cochrane Database of Systematic Reviews 12: CD012519. https://doi.org/10.1002/14651858.CD012519.pub2
-
Hauth, J.C., Goldenberg, R.L., Andrews, W.W., DuBard, M.B. and Copper, R.L., 1995. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. New England Journal of Medicine 333: 1732-1736. https://doi.org/10.1056/NEJM199512283332603
-
Hemmerling, A., Harrison, W., Schroeder, A., Park, J., Korn, A., Shiboski, S. and Cohen, C.R., 2009. Phase 1 dose-ranging safety trial of Lactobacillus crispatus CTV-05 (LACTIN-V) for the prevention of bacterial vaginosis. Sexually Transmitted Diseases 36: 564. https://doi.org/10.1097/OLQ.0b013e3181a74924.
-
Hemmerling, A., Harrison, W., Schroeder, A., Park, J., Korn, A., Shiboski, S., Foster-Rosales, A. and Cohen, C.R., 2010. Phase 2a study assessing colonization efficiency, safety, and acceptability of Lactobacillus crispatus CTV-05 in women with bacterial vaginosis. Sexually Transmitted Diseases 37: 745-750. https://doi.org/10.1097/OLQ.0b013e3181e5
-
Husain, S., Allotey, J., Drymoussi, Z., Wilks, M., Fernandez-Felix, B., Whiley, A., Dodds, J., Thangaratinam, S., McCourt, C. and Prosdocimi, E., 2020. Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis. BJOG 127: 275-284. https://doi.org/10.1111/1471-0528.15675
-
Jones, A.J., Eke, U.A. and Eke, A.C., 2022. Prediction and prevention of preterm birth in pregnant women living with HIV on antiretroviral therapy. Expert Review of Anti-Infective Therapy 20: 837-848. Khaskheli, M., Baloch, S., Baloch, A.S. and Shah, S.G.S., 2021. Vaginal discharge during pregnancy and associated adverse maternal and perinatal outcomes. Pakistan Journal of Medical Sciences 37: 1302. https://doi.org/10.12669/pjms.37.5.4187
-
Kindinger, L.M., Bennett, P.R., Lee, Y.S., Marchesi, J.R., Smith, A., Cacciatore, S., Holmes, E., Nicholson, J.K., Teoh, T.G. and MacIntyre, D.A., 2017. The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk. Microbiome 5: 6. https://doi.org/10.1186/s40168-016-0223-9
-
Kindinger, L.M., MacIntyre, D.A., Lee, Y.S., Marchesi, J.R., Smith, A., McDonald, J.A., Terzidou, V., Cook, J.R., Lees, C., Israfil-Bayli, F., Faiza, Y., Toozs-Hobson, P., Slack, M., Cacciatore, S., Holmes, E., Nicholson, J.K., Teoh, T.G. and Bennett, P.R., 2016. Relationship between vaginal microbial dysbiosis, inflammation, and pregnancy outcomes in cervical cerclage. Science Translational Medicine 8: 350ra102. https://doi.org/10.1126/scitranslmed.aag1026
-
Kyrgiou, M., Athanasiou, A., Paraskevaidi, M., Mitra, A., Kalliala, I., Martin-Hirsch, P., Arbyn, M., Bennett, P. and Paraskevaidis, E., 2016. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ 354. https://doi.org/10.1136/bmj.i3633
-
Lamont, R.F., Duncan, S.L., Mandal, D. and Bassett, P., 2003. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstetrics and Gynecology 101: 516-522. https://doi.org/10.1016/S0029-7844(02)03054-5
-
MacIntyre, D.A., Sykes, L. and Bennett, P.R., 2017. The human female urogenital microbiome: complexity in normality. Emerging Topics in Life Sciences 1: 363-372. https://doi.org/10.1042/ETLS20170042
-
Marrazzo, J.M., Cook, R.L., Wiesenfeld, H.C., Murray, P.J., Busse, B., Krohn, M. and Hillier, S.L., 2006. Women’s satisfaction with an intravaginal Lactobacillus capsule for the treatment of bacterial vaginosis. Journal of Women’s Health 15: 1053-1060.https://doi.org/10.1089/jwh.2006.15.1053
-
Mastromarino, P., Di Pietro, M., Schiavoni, G., Nardis, C., Gentile, M. and Sessa, R., 2014. Effects of vaginal lactobacilli in Chlamydia trachomatis infection. International Journal of Medical Microbiology 304: 654-661. https://doi.org/10.1016/j.ijmm.2014.04.006
-
McDonald, H., O’loughlin, J., Vigneswaran, R., Jolley, P., Harvey, J., Bof, A. and McDonald, P., 1997. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial. BJOG: An International Journal of Obstetrics and Gynaecology 104: 1391-1397. https://doi.org/10.1111/j.1471-0528.1997.tb11009.x
-
Nordqvist, M., Jacobsson, B., Brantsæter, A.-L., Myhre, R., Nilsson, S. and Sengpiel, V., 2018. Timing of probiotic milk consumption during pregnancy and effects on the incidence of preeclampsia and preterm delivery: a prospective observational cohort study in Norway. BMJ Open 8: e018021. https://doi.org/10.1136/bmjopen-2017-018021
-
Payne, M.S., Newnham, J.P., Doherty, D.A., Furfaro, L.L., Pendal, N.L., Loh, D.E. and Keelan, J.A., 2021. A specific bacterial DNA signature in the vagina of Australian women in midpregnancy predicts high risk of spontaneous preterm birth (the Predict1000 study). Am Journal of Obstetrics and Gynecology 224: 206 e201-206 e223. https://doi.org/10.1016/j.ajog.2020.08.034
-
Piette, P.C., 2020. The pharmacodynamics and safety of progesterone. Best Practice & Research Clinical Obstetrics and Gynaecology 69: 13-29. https://doi.org/10.1016/j.bpobgyn.2020.06.002
-
Pruski, P., Lewis, H.V., Lee, Y.S., Marchesi, J.R., Bennett, P.R., Takats, Z. and MacIntyre, D.A., 2018. Assessment of microbiota: host interactions at the vaginal mucosa interface. Methods 149: 74-84. https://doi.org/10.1016/j.ymeth.2018.04.022
-
Reid, G., Charbonneau, D., Erb, J., Kochanowski, B., Beuerman, D., Poehner, R. and Bruce, A.W., 2003. Oral use of Lactobacillus rhamnosus GR-1 and L.fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunology and Medical Microbiology 35: 131-134. https://doi.org/10.1016/S0928-8244(02)00465-0
-
Rizzo, A., Fiorentino, M., Buommino, E., Donnarumma, G., Losacco, A. and Bevilacqua, N., 2015. Lactobacillus crispatus mediates antiinflammatory cytokine interleukin-10 induction in response to Chlamydia trachomatis infection in vitro. International Journal of Medical Microbiology 305: 815-827. https://doi.org/10.1016/j.ijmm.2015.07.005
-
Rizzo, A., Losacco, A. and Carratelli, C.R., 2013. Lactobacillus crispatus modulates epithelial cell defense against Candida albicans through Toll-like receptors 2 and 4, interleukin 8 and human ß-defensins 2 and 3. Immunology Letters 156: 102-109. https://doi.org/10.1016/j.imlet.2013.08.013
-
Rybalchenko, O.V., Bondarenko, V.M., Orlova, O.G., Markov, A.G. and Amasheh, S., 2015. Inhibitory effects of Lactobacillus fermentum on microbial growth and biofilm formation. Archives of Microbiology 197: 1027-1032. https://doi.org/10.1007/s00203-015-1140-1
-
Spurbeck, R.R. and Arvidson, C.G., 2008. Inhibition of Neisseria gonorrhoeae epithelial cell interactions by vaginal Lactobacillus species. Infection and Immunity 76: 3124-3130.https://doi.org/10.1128/IAI.00101-08
-
Stapleton, A.E., Au-Yeung, M., Hooton, T.M., Fredricks, D.N., Roberts, P.L., Czaja, C.A., Yarova-Yarovaya, Y., Fiedler, T., Cox, M. and Stamm, W.E., 2011. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clinical Infectious Diseases 52: 1212-1217. https://doi.org/10.1093/cid/cir183
-
Strömmer, S., Lawrence, W., Rose, T., Vogel, C., Watson, D., Bottell, J.N., Parmenter, J., Harvey, N.C., Cooper, C. and Inskip, H., 2018. Improving recruitment to clinical trials during pregnancy: a mixed methods investigation. Social Science and Medicine 200: 73-82. https://doi.org/10.1016/j.socscimed.2018.01.014
-
Tomás, M.S.J., Duhart, C.I.S., De Gregorio, P.R., Pingitore, E.V. and Nader-Macías, M.E., 2011. Urogenital pathogen inhibition and compatibility between vaginal Lactobacillus strains to be considered as probiotic candidates. European Journal of Obstetrics and Gynecology and Reproductive Biology 159: 399-406. https://doi.org/10.1016/j.ejogrb.2011.07.010
-
U.S. Department of Health and Human Services (USDHHS), 2017. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events, corrected version 2.1. USDHHS, National Institute of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS (DAIDS), USA. Available at: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf
-
Uehara, S., Monden, K., Nomoto, K., Seno, Y., Kariyama, R. and Kumon, H., 2006. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. International Journal of Antimicrobial Agents 28: 30-34. https://doi.org/10.1016/j.ijantimicag.2006.05.008
-
Veščičík, P., Musilová, K., Stranik, J., Štěpán, M. and Kacerovský, M., 2020. Lactobacillus crispatus dominant vaginal microbita in pregnancy. Ceska Gynekologie 85: 67-70.
'Lactobacillus crispatus dominant vaginal microbita in pregnancy ' () 85 Ceska Gynekologie : 67 -70.
-
Wada, K., Uehara, S., Ishii, A., Sadahira, T., Yamamoto, M., Mitsuhata, R., Takamoto, A., Araki, M., Kobayashi, Y. and Watanabe, M., 2016. A Phase II clinical trial evaluating the preventive effectiveness of lactobacillus vaginal suppositories in patients with recurrent cystitis. Acta Medica Okayama 70: 299-302. https://doi.org/10.18926/AMO/54508
-
Williams, C., Fong, R., Murray, S.M. and Stock, S.J., 2021. Caesarean birth and risk of subsequent preterm birth: a retrospective cohort study. BJOG 128: 1020-1028.
'Caesarean birth and risk of subsequent preterm birth: a retrospective cohort study ' () 128 BJOG : 1020 -1028.
-
Yang, S., Reid, G., Challis, J.R., Gloor, G.B., Asztalos, E., Money, D., Seney, S. and Bocking, A.D., 2020. Effect of oral probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 on the vaginal microbiota, cytokines and chemokines in pregnant women. Nutrients 12: 368. https://doi.org/10.3390/nu12020368
-
Yefet, E., Colodner, R., Strauss, M., Gam Ze Letova, Y. and Nachum, Z., 2020. A randomized controlled open label crossover trial to study vaginal colonization of orally administered Lactobacillus reuteri RC-14 and rhamnosus GR-1 in pregnant women at high risk for preterm labor. Nutrients 12: 1141. https://doi.org/10.3390/nu12041141
Supplementary Materials
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1233 | 1197 | 99 |
| Full Text Views | 48 | 28 | 4 |
| PDF Views & Downloads | 70 | 52 | 5 |
Safety, tolerability, and acceptability of Lactobacillus crispatus CTV-05 (LACTIN-V) in pregnant women at high-risk of preterm birth
In: Beneficial MicrobesMarch of Dimes European Prematurity Research Centre, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, UK, United Kingdom.
Search for other papers by E. Bayar in
Current site
Google Scholar
PubMed
March of Dimes European Prematurity Research Centre, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, UK, United Kingdom.
Tommy’s National Centre for Miscarriage Research. Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, United Kingdom.
Search for other papers by D.A. MacIntyre in
Current site
Google Scholar
PubMed
March of Dimes European Prematurity Research Centre, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, UK, United Kingdom.
The Parasol Foundation Centre for Women’s Health and Cancer Research, St Mary’s Hospital, Imperial College Healthcare NHS Trust, London, W2 1NY.
Search for other papers by L. Sykes in
Current site
Google Scholar
PubMed
March of Dimes European Prematurity Research Centre, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, UK, United Kingdom.
Search for other papers by K. Mountain in
Current site
Google Scholar
PubMed
Search for other papers by T.P. Parks in
Current site
Google Scholar
PubMed
Search for other papers by P.P. Lee in
Current site
Google Scholar
PubMed
March of Dimes European Prematurity Research Centre, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, UK, United Kingdom.
Tommy’s National Centre for Miscarriage Research. Imperial College London, Hammersmith Hospital Campus, Du Cane Road, W120NN London, United Kingdom.
Search for other papers by P.R. Bennett in
Current site
Google Scholar
PubMed
The vaginal microbiota is a determinant for the risk of preterm birth (PTB). Dominance of the vaginal niche by Lactobacillus crispatus associates with term delivery. This is the first observational clinical study of live vaginal biotherapeutics (Lactobacillus crispatus CTV-05 (LACTIN-V)) in pregnant women at high-risk of PTB. The primary aim was to explore safety, tolerability and acceptability of LACTIN-V in pregnancy. Women were offered a course of LACTIN-V at 14 weeks gestation for five consecutive days followed by weekly administration for six weeks. Participants were followed up at 15, 18-, 20-, 28- and 36-weeks’ gestation and at delivery for assessment of adverse events, compliance and tolerability. Participants completed a questionnaire to gauge experience and acceptability. In total, 73 women were recruited, of whom eight withdrew, leaving a final cohort size of 61. Self-reported compliance to the course was high (56/60, 93%). Solicited adverse events were reported in 13 women (19%) including changes in vaginal discharge, odour, colour or consistency of urine, itching and vaginal bleeding. One unsolicited adverse event was reported as haematuria at 38 weeks gestation, but was judged to be unrelated to LACTIN-V. No serious adverse events occurred. One mild adverse event led to study withdrawal. Thirty-one women completed an experience and acceptability questionnaire. Women found LACTIN-V easy and comfortable to use and the majority (30/31, 97%) would use LACTIN-V in future pregnancies. Eight women (8/31, 26%) found the schedule of use difficult to remember. The rate of PTB <34 weeks in this cohort was 3.3% compared to 7% in a historical cohort of 2,190 women at similar background PTB risk. With satisfactory uptake and good compliance, we demonstrate that LACTIN-V is safe and accepted in pregnancy, with high tolerability. Further studies are needed to assess colonisation of Lactobacillus crispatus CTV-05 and clinical efficacy.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1233 | 1197 | 99 |
| Full Text Views | 48 | 28 | 4 |
| PDF Views & Downloads | 70 | 52 | 5 |